Drug Trial Radar · NCT07684612
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
690
Planned (sponsor's estimate)
Start
Sep 8, 2026
Primary completion
May 21, 2030
Study completion Apr 22, 2033
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GOG, ENGOT, APGOT
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.
Conditions
- Ovarian Neoplasms
Interventions
Mocertatug rezetecan (Mo-Rez)Drug
Mocertatug rezetecan will be administered
CarboplatinDrug
Carboplatin will be administered
PaclitaxelDrug
Paclitaxel will be administered
GemcitabineDrug
Gemcitabine will be administered
Pegylated liposomal doxorubicin (PLD)Drug
PLD will be administered
BevacizumabDrug
Bevacizumab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by BICRTime frame: Up to approximately 191 weeks
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Newcastle, New South Wales, Australia · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Hokkaido, Japan · Recruiting
GSK Investigational Site
Hyōgo, Japan · Recruiting
GSK Investigational Site
Ibaraki, Japan · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.